Introduction
============

Patients with Crohn's disease (CD) reveal various malnutrition statuses \[[@B1]--[@B3]\]. In many studies, deficiencies in trace elements, such as selenium and zinc, have been reported as characteristic features of malnutrition in CD patients \[[@B4]--[@B7]\]. Insufficient oral intake and malabsorption have been considered to be the major causes of trace element deficiencies \[[@B1]\]. Surgical resection of the small intestine may also reduce the absorption activity of trace elements through decreases in the mucosal absorption area. In addition, since parenteral and enteral nutrition are widely accepted to be effective for inducing and maintaining remission \[[@B8]--[@B10]\], CD patients sometimes receive parenteral or enteral nutrition for the management of their disease. Most of the parenteral and enteral formulas commonly used in Japan and the USA do not contain sufficient trace elements \[[@B8], [@B10]--[@B12]\], and lead to inadequate supplies of trace elements. In particular, long-term treatment with parentaral or enteral nutrition may induce high-risk trace element deficiencies in CD patients.

In this study, we investigated the trace element status in CD patients, and evaluated the effects of trace element-rich supplementation.

Subjects and Methods
====================

Patients
--------

Thirty-one patients with CD (9 women and 22 men, median age 31 years old) receiving home enteral nutrition were enrolled in this study. All patients were managed in the Division of Gastroenterology at the Hospital of the Shiga University of Medical Science. The ethics committee of the Shiga University of Medical Science approved this study. All patients had the diagnosis of CD established by radiological, histological, and clinical criteria.

All patients had low disease activities \[Crohn's disease activity index (CDAI)\<150 \[[@B13]\]\], and these patients were regarded as inactive phase. All patients were placed on an enteral nutrition regimen with Elental® (Ajinomoto pharmaceutical. Ltd., Tokyo, Japan). The daily caloric intake from the enteral nutrition was 1,093 ± 239 (mean ± SD) kcal for over 1 year. The Elental® formula contains a very small amount of selenium and zinc.

A selenium and zinc-rich supplement (V-Accel®, Nutri Co., Tokyo, japan) was used. The daily dosage of V-Acccel® contained 100 µg selenium and 10 mg zinc.

Blood was sampled with the patients' informed consent, immediately separated to serum by centrifugation, and kept at −80°C until use.

Analytical methods
------------------

Serum selenium and zinc concentrations were determined by atomic absorption spectroscopy. Other laboratory data were measured by routine methods at the Hospital of the Shiga University of Medical Science. Serum selenoprotein P levels were determined by a previously described ELISA system \[[@B6]\]. Glutathione peroxidase (GPx) activity was determined by a method described by Lowrence *et al.* \[[@B14]\].

Statistical analysis
--------------------

Differences between groups were analyzed with the Kruskal-Wallis test. A *p* value\<0.05 was considered to be statistically significant. Correlations were investigated with Spearman rank correlation test.

Result
======

Serum levels of albumin, selenium, zinc and copper were determined in 31 CD patients receiving eneteral nutrition. In our hospital, normal ranges of serum levels of albumin, selenium, zinc and copper ranged from 4.0 to 5.2 g/dl, from 10.6 to 17.4 µg/dl, from 64 to 111 µg/dl, and from 70 to 132 µg/dl, respectively. As shown in Fig. [1](#F1){ref-type="fig"}, average levels of albumin, selenium, zinc and copper were 4.1 ± 0.4 g/dl, 11.2 ± 2.8 µg/dl, 71.0 ± 14.8 µg/dl, and 112.0 ± 25.6 µg/dl, respectively. In 9 of the 31 CD analyzed patients, serum albumin levels were lower than the lower limit of the normal range. Similarly, serum selenium, zinc and copper levels were lower than the lower limits in 12 patients, 9 patients and 1 patient, respectively.

Selenium is incorporated into proteins via the selenium-containing amino acids selenocysteine and selenomethionine. A selenoprotein is a selenocystein-containing protein, and GPx and selenoprotein P are representative serum selenoproteins. To clarify the significance of serum selenium levels, we assessed the relationship between serum selenium and selenoprotein P levels and the relationship between serum selenium levels and GPx activity. As shown in Fig. [2](#F2){ref-type="fig"}, a significant correlation was found between serum selenium and selenoprotein P levels and between serum selenium and GPx activity, respectively. However, there are no significant correlations between serum albumin levels and these factors (serum selenium, selenoprotein P and GPx activity).

In 8 patients whose serum selenium levels were under the lower limit of normal range, we evaluated the effects of selenium- and zinc-rich supplementation. In these patients, no significant correlation between serum trace element levels and albumin levels was observed. Patients orally received selenium-and zinc-rich supplement, and after 2 months changes in serum selenium and zinc levels were determined. The daily dosage of the supplement contained 100 µg of selenium and 10 mg of zinc. As shown in Fig. [3](#F3){ref-type="fig"}, administration of the selenium- and zinc-rich supplement significantly increased serum selenium, zinc levels and GPx activitiy. However, due to a lack of copper in the supplement, copper levels were not affected. Serum albumin levels did not change after supplementation.

Discussion
==========

Deficiencies in trace elements, such as selenium and zinc, have been reported in various clinical studies as an indication of malnutrition in CD patients \[[@B4], [@B7], [@B8], [@B15]--[@B17]\]. Selenium is an essential trace element that is a component of GPx, a scavenger of hydroperoxides \[[@B18]\]. A selenium deficiency causes a decrease in GPx function, thereby resulting in oxidative damage to many organs. In humans severe selenium deficiencies have been linked to the development of Keshan disease, a dilated congestive cardiomyopathy that primarily occurs in children living in China \[[@B19]\]. Zinc is present in over 80 metalloenzymes that are involved in all the major human metabolic pathways in humans. Zinc is necessary for cell proliferation and has an important role in the maintenance of cellular immunity \[[@B16], [@B17]\]. An acute zinc deficiency leads to the development of acrodermatitis, alopecia, diarrhea and depression, and chronic zinc deficiencies cause growth retardation, anorexia, immune disturbance and skin lesions \[[@B16]\].

In this study, we observed that serum selenium and zinc levels were lower than the lower limits of normal ranges in 38.7 and 29.0 % of CD patients receiving enteral nutrition for a long time period, respectively. In contrast, copper levels were normal in most of the patients. The findings reported herein are consistent with previous reports \[[@B4], [@B15]\].

Trace element deficiencies in CD patients may result from a variety of processes, including reduced dietary intake, impaired mucosal absorption, increased excretion, and hypoalbuminemia \[[@B16]\]. In these processes, two factors may be important: mucosal malabsorption of trace elements and trace element-deficient nutrition. Nishida *et al.* previously demonstrated that zinc absorption is reduced even in histologically normal jejunal mucosa \[[@B20]\]. A similar mechanism might be applied for selenium absorption. CD patients sometimes receive parenteral nutrition or enteral nutrition for the management of malnutrition \[[@B8]--[@B10]\], and selenium and zinc deficiencies occurs in CD patients who are nourished alone by parentaral or enteral nutrition for a long period of time \[[@B7], [@B8], [@B10], [@B11]\]. Trace element deficiencies are associated with inadequate supplies of trace elements by parentaral and enteral nutrition, since most of the parentaral or enteral formulas do not contain sufficient trace elements \[[@B8], [@B10]--[@B12]\]. Thus, with the use of parenteral and enteral nutrition in CD patients, much attention should be paid to avoid the development of trace element deficiencies. All of our cases were inactive phase of disease, and major factor contributed to low serum selenium and zinc levels might be inadequate supplies of trace elements by enteral nutrition.

Selenoprotein P contains 10 selenocystein residues per molecule, and is a plasma protein that carries more than 50% of the plasma selenium \[[@B6], [@B21], [@B22]\]. Selenoprotein P is an important selenium supplier from the liver to the peripheral tissues \[[@B22]\]. More importantly, selenoprotein P is a free radical scavenger for peroxynitrite and phospholipid-hydroperoxide \[[@B6]\]. Like GPx, selenoprotein P is an important serum antioxidant factor, and protects cells from oxidative stress. In this study, serum selenium levels were associated with serum selenoprotein P levels and GPx activity, suggesting that the antioxidant status might be reduced in CD patients receiving enteral nutrition for a long period of time. Since it has been suggested that active oxygen species play an important role in the pathogenesis of inflammatory bowel diseases (IBD) \[[@B6], [@B18]\], improvements in the selenium status might be relevant to reduce disease activity.

Based on findings of lower serum trace element levels, we orally administered selenium and zinc-rich supplement in 8 patients. As initially expected, selenium and zinc supplementation significantly improved selenium and zinc-status in these patients. Although no consensus has been reached on the dosage of trace elements to be administered, the recommended therapeutic dose of selenium ranges from 100 µg to 400 µg/day \[[@B23], [@B24]\]. Zinc requirements range from 2 mg to 12 mg/day \[[@B16]\]. Our supplementation formula consisted of 100 µg/day of selenium and 10 mg/day of zinc, and was sufficient for CD patients receiving enteral nutrition. Improvements in the trace element status suggest that trace element supplementation should be performed in CD patients receiving long-term entral nutrition. No patients showed symptoms of lower trace elements, and this might be du to that clinical symptoms appear as a result of longer-term and much severer reduction of serum trace element levels. However, the antioxidant status in these patients might be recovered through improvement in selenium deficiency.

In conclusion, selenium and zinc deficiencies should be considered in CD patients receiving enteral nutrition for a long period of time. In these patients, selenium (100 µg/day) and zinc (10 mg/day) supplementation for 2 months was effective in improving the trace element status.
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